Sisram Medical Valuation

Q: What is the Fair Price of 1696 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1696 (HK$3.36) is trading below our estimate of [[fair value]] (HK$29.8)

Is 1696 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1696 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1696 (HK$3.36) is trading below our estimate of fair value (HK$29.8)

Significantly Below Fair Value: 1696 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1696?

Key metric: As 1696 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1696. This is calculated by dividing 1696's market cap by their current earnings.
What is 1696's PE Ratio?
PE Ratio	8.6x
Earnings	US$23.55m
Market Cap	US$200.99m

1696 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.5x
Enterprise Value/EBITDA	4.6x
PEG Ratio	0.4x

Price to Earnings Ratio vs Peers

How does 1696's PE Ratio compare to its peers?

The above table shows the PE ratio for 1696 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	24.8x
2407 Gaush Meditech	15.5x	n/a	HK$1.6b
1358 PW Medtech Group	9.3x	n/a	HK$1.5b
6669 Acotec Scientific Holdings	66.3x	68.0%	HK$2.3b
3600 Modern Dental Group	8.2x	16.5%	HK$3.4b
1696 Sisram Medical	8.6x	24.2%	HK$1.6b

Price-To-Earnings vs Peers: 1696 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the peer average (24.8x).

Price to Earnings Ratio vs Industry

How does 1696's PE Ratio compare vs other companies in the HK Medical Equipment Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
2393 Yestar Healthcare Holdings	0.1x	n/a	US$21.27m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 1696 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the Hong Kong Medical Equipment industry average (15.9x).

Price to Earnings Ratio vs Fair Ratio

What is 1696's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1696 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	8.6x
Fair PE Ratio	14.6x

Price-To-Earnings vs Fair Ratio: 1696 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the estimated Fair Price-To-Earnings Ratio (14.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1696 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	HK$3.36	HK$5.74 +70.9%	21.6%	HK$6.98	HK$4.50	n/a	2
Nov ’25	HK$3.56	HK$5.74 +61.3%	21.6%	HK$6.98	HK$4.50	n/a	2
Oct ’25	HK$4.04	HK$5.74 +42.1%	21.6%	HK$6.98	HK$4.50	n/a	2
Sep ’25	HK$3.21	HK$5.74 +78.9%	21.6%	HK$6.98	HK$4.50	n/a	2
Aug ’25	HK$3.10	HK$6.10 +96.8%	14.8%	HK$7.00	HK$5.20	n/a	2
Jul ’25	HK$3.60	HK$6.10 +69.4%	14.8%	HK$7.00	HK$5.20	n/a	2
Jun ’25	HK$3.76	HK$6.10 +62.2%	14.8%	HK$7.00	HK$5.20	n/a	2
May ’25	HK$3.68	HK$6.10 +65.8%	14.8%	HK$7.00	HK$5.20	n/a	2
Apr ’25	HK$3.53	HK$6.10 +72.8%	14.8%	HK$7.00	HK$5.20	n/a	2
Mar ’25	HK$4.05	HK$9.83 +142.8%	11.5%	HK$10.97	HK$8.70	n/a	2
Feb ’25	HK$4.00	HK$9.83 +145.9%	11.5%	HK$10.97	HK$8.70	n/a	2
Jan ’25	HK$5.26	HK$9.83 +87.0%	11.5%	HK$10.97	HK$8.70	n/a	2
Dec ’24	HK$5.18	HK$9.83 +89.8%	11.5%	HK$10.97	HK$8.70	n/a	2
Nov ’24	HK$4.95	HK$9.83 +98.7%	11.5%	HK$10.97	HK$8.70	HK$3.56	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

OrbusNeich Medical Group Holdings

HK$3.4b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

6929

HK$4.17

2.5%

-47.8%

Sinopharm Group

HK$66.5b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.55

1.5%

3.1%

MicroPort Scientific

HK$11.5b

An investment holding company, engages in the manufacture, marketing, and sale of medical devices in the People’s Republic of China, North America, Europe, rest of Asia, South America, and internationally.

853

HK$6.01

-4.5%

-54.8%